Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL682799 | 0.91 | RXFP1 (0.60) | LMNASMN1; SMN2POLBRXFP1ALDH1A1 | |
| SCHEMBL683975 | 0.87 | LMNA (0.65) | LMNASMN1; SMN2POLBMAPK1RXFP1 | |
| SCHEMBL683965 | 0.85 | LMNA (0.58) | LMNASMN1; SMN2POLBMAPK1RXFP1 | |
| SCHEMBL682806 | 0.84 | LMNA (0.62) | LMNASMN1; SMN2POLBMAPK1RXFP1 | |
| SCHEMBL683586 | 0.83 | ALDH1A1 (0.74) | LMNASMN1; SMN2POLBMAPK1RXFP1 | |
| SCHEMBL10573674 | 0.83 | LMNA (0.59) | LMNASMN1; SMN2POLBMAPK1RXFP1 | |
| SCHEMBL10569220 | 0.82 | LMNA (0.58) | LMNASMN1; SMN2POLBMAPK1RXFP1 | |
| SCHEMBL11123833 | 0.81 | LMNA (0.75) | LMNASMN1; SMN2POLBRXFP1ALDH1A1 | |
| SCHEMBL682803 | 0.81 | SMN1; SMN2 (0.57) | LMNASMN1; SMN2POLBMAPK1RXFP1 | |
| SCHEMBL10565435 | 0.80 | LMNA (0.57) | LMNASMN1; SMN2POLBMAPK1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | LMNA 2155/4885SMN1; SMN2 907/4885POLB 1723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.